NANOBIOTIX AND BIOTECHCORP TO FOCUS COLLABORATION ON TROPICAL DISEASES

KUALA LUMPUR, Sept 24 (Bernama) -- Nanobiotix, a nanomedicine company
focused on cancer therapy, and its partner the Malaysian Biotechnology
Corporation Sdn Bhd (BiotechCorp), will initially focus their collaboration on
developing point-of-care diagnostics as well as drug delivery systems for
tropical diseases, such as Malaria.

BiotechCorp has acquired an exclusive, global license to a Nanobiotix
nanotechnology platform for non-cancer purposes.

As part of the collaboration, three scientists identified by BiotechCorp
will take up residence at Nanobiotix for a year to undergo technology
transfer training.

"We firmly believe that the opportunity to help save millions of lives is
in fact a near-term possibility as a result of this collaboration.

"Additionally, it is a significant testimony to the readiness of the
Malaysian biotechnology industry in commercialising science, whilst addressing
challenges in our part of the world," said BiotechCorp's chief executive
officer, Iskandar Mizal Mahmood.

According to Nanobiotix president and chief executive officer and
co-president of the French Technology Platform on Nanotechnology, Lauren Levy,
BiotechCorp offers Nanobiotix a direct route to Asia.

"Certainly BiotechCorp's strategic location in the heart of Asia, along
with Malaysia's pro-business government, political stability, entreprenuer
spirit and the cost effective base for doing business, are among the many good
reasons we have chosen to partner it," he said.